ArticleGynecologic oncology reports2025

Pembrolizumab and lenvatinib in the treatment of recurrent ovarian carcinoma: A single institution experience.

Helen Toma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.